David A. Mahvi

ORCID: 0000-0003-2722-8518
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cardiac, Anesthesia and Surgical Outcomes
  • Pancreatic and Hepatic Oncology Research
  • Immunotherapy and Immune Responses
  • Enhanced Recovery After Surgery
  • Colorectal Cancer Screening and Detection
  • Cancer Treatment and Pharmacology
  • CAR-T cell therapy research
  • COVID-19 and healthcare impacts
  • Electrospun Nanofibers in Biomedical Applications
  • Sarcoma Diagnosis and Treatment
  • Chemotherapy-induced cardiotoxicity and mitigation
  • Melanoma and MAPK Pathways
  • Thyroid and Parathyroid Surgery
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Advances in Oncology and Radiotherapy
  • Gastric Cancer Management and Outcomes
  • Colorectal Cancer Surgical Treatments
  • Thyroid Cancer Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • Gastrointestinal Tumor Research and Treatment
  • Immune Cell Function and Interaction
  • Nonmelanoma Skin Cancer Studies
  • Nanoparticle-Based Drug Delivery
  • Nutrition and Health in Aging
  • HER2/EGFR in Cancer Research

Medical University of South Carolina
2020-2024

Brigham and Women's Hospital
2016-2023

Harvard University
2016-2023

Institut de Virologie
2021-2022

Massachusetts General Hospital
2019-2022

NIHR Birmingham Biomedical Research Centre
2021

University of Birmingham
2021

Yorkshire Cancer Research
2021

Urology Foundation
2021

Association for Cancer Surgery
2021

We studied the effectiveness of monoclonal anti-CD40 + cytosine–phosphate–guanosine-containing oligodeoxynucleotide 1826 (CpG-ODN) immunotherapy (IT) in mice treated with multidrug chemotherapy (CT) consisting vincristine, cyclophosphamide and doxorubicin. Combining CT IT led to synergistic anti-tumour effects C57BL/6 established B16 melanoma or 9464D neuroblastoma. suppressed functions T cells natural killer (NK) cells, but primed naïve peritoneal macrophages (Mφ) vitro stimulation...

10.1111/j.1365-2567.2010.03357.x article EN Immunology 2010-10-13

Background : Increased intracellular glutathione has long been associated with tumor cell resistance to various cytotoxic agents. An inhibitor of biosynthesis, l -S,Rbuthionine sulfoximine (BSO), shown enhance the cytotoxicity chemotherapeutic agents in vitro and vivo . We performed a phase I study BSO administered anticancer drug melphalan determine combination's safety/tolerability clinically whether produced desired biochemical end point depletion (<10% pretreatment value). Methods...

10.1093/jnci/89.23.1789 article EN JNCI Journal of the National Cancer Institute 1997-12-03

Pneumatosis intestinalis (PI) is a rare radiographic finding that can range from being benign process to needing emergency surgery. Sufficiently powered studies are lacking, and recommendations for management remain unclear. The purpose of this study was identify key predictors pathologic PI using physical examination, laboratory, findings. A retrospective cohort conducted at two quaternary academic centers (2010-2020). total 334 consecutive patients 18 years or older with evidence were...

10.1097/ta.0000000000004548 article EN Journal of Trauma and Acute Care Surgery 2025-02-13

Immunotherapeutic approaches to the treatment of advanced melanoma have relied on strategies that augment responsiveness endogenous tumor-specific T-cell populations [eg, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade-mediated checkpoint inhibition] or introduce exogenously prepared adoptive cell transfer (ACT)]. Although both shown considerable promise, response rates these therapies remain suboptimal. We hypothesized a combinatorial approach immunotherapy using CTLA-4...

10.1097/cji.0000000000000064 article EN Journal of Immunotherapy 2015-02-01

Although cancer cachexia is classically characterized as a systemic inflammatory disorder, emerging evidence indicates that weight loss also associates with local tissue inflammation. We queried the regulation of this inflammation and its causality to by exploring skeletal muscle, whose atrophy strongly poor outcomes. Using multiple mouse models patient samples, we show cachectic muscle marked enhanced innate immunity. Nuclear factor κB (NF-κB) activity in cells, including satellite...

10.1016/j.celrep.2024.114925 article EN cc-by-nc-nd Cell Reports 2024-10-31

Several studies have identified disparities in pancreatic cancer treatment associated with gender, race, and ethnicity. There are limited data examining short-term adverse outcomes after resection for cancer. The aim of this study is to evaluate associations ethnicity morbidity mortality malignancy.The American College Surgeons National Surgical Quality Improvement database was retrospectively reviewed. χ2 test Student's t-test were used univariable analysis hierarchical logistic regression...

10.1002/jso.26748 article EN Journal of Surgical Oncology 2021-11-16

Surgery is the only potentially curative treatment for localized soft-tissue sarcomas. However, sarcomas arising in retroperitoneum, locoregional recurrence rates are 35% to 59% despite resection. Doxorubicin (DOX) standard first-line systemic chemotherapy advanced sarcoma, yet its intravenous administration yields limited clinical efficacy and results dose-limiting cardiotoxicity. We report fabrication optimization of a novel electrospun poly(caprolactone) (PCL) surgical mesh coated with...

10.1158/0008-5472.can-22-0734 article EN Cancer Research 2022-09-28

Abstract Cancer cachexia is a debilitating syndrome characterized by unintentional weight loss largely due to the depletion of adipose and skeletal muscle mass. Cachexia occurs in at least half all patients with cancer, increasing incidences more advanced cases, estimated be responsible for greater than 20% cancer related deaths. In pancreatic ductal adenocarcinoma (PDAC), which has 5-year survival rate 13%, incidence can as high 80% associated poor disease outcomes. Mitigating effects...

10.1158/1538-7445.pancreatic24-b014 article EN Cancer Research 2024-09-15
Coming Soon ...